These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18563511)

  • 1. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo.
    Meyer HE; Lofthus CM; Søgaard AJ; Falch JA
    Osteoporos Int; 2009 May; 20(5):827-30. PubMed ID: 18563511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway.
    Støen RO; Nordsletten L; Meyer HE; Frihagen JF; Falch JA; Lofthus CM
    Osteoporos Int; 2012 Oct; 23(10):2527-34. PubMed ID: 22246602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study.
    Mosekilde L; Beck-Nielsen H; Sørensen OH; Nielsen SP; Charles P; Vestergaard P; Hermann AP; Gram J; Hansen TB; Abrahamsen B; Ebbesen EN; Stilgren L; Jensen LB; Brot C; Hansen B; Tofteng CL; Eiken P; Kolthoff N
    Maturitas; 2000 Oct; 36(3):181-93. PubMed ID: 11063900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between hand-grip strength and site-specific risks of major osteoporotic fracture: Results from the Japanese Population-based Osteoporosis Cohort Study.
    Kamiya K; Kajita E; Tachiki T; Ikehara S; Kouda K; Sato Y; Tamaki J; Kagamimori S; Iki M
    Maturitas; 2019 Dec; 130():13-20. PubMed ID: 31706431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women.
    Crandall CJ; Larson J; Wright NC; Laddu D; Stefanick ML; Kaunitz AM; Watts NB; Wactawski-Wende J; Womack CR; Johnson KC; Carbone LD; Jackson RD; Ensrud KE
    JAMA Intern Med; 2020 Sep; 180(9):1232-1240. PubMed ID: 32730575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of distal forearm fractures in Oslo, Norway.
    Lofthus CM; Frihagen F; Meyer HE; Nordsletten L; Melhuus K; Falch JA
    Osteoporos Int; 2008 Jun; 19(6):781-6. PubMed ID: 17985071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of hip fracture in Oslo, Norway: differences within the city.
    Kaastad TS; Meyer HE; Falch JA
    Bone; 1998 Feb; 22(2):175-8. PubMed ID: 9477241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased reduction in bone density and skin thickness in postmenopausal women on long-term corticosteroid therapy. A suggested role for estrogen add back therapy.
    Baron YM; Brincat M; Galea R
    Adv Exp Med Biol; 1999; 455():429-36. PubMed ID: 10599380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
    Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
    J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of hip fractures in Oslo, Norway.
    Lofthus CM; Osnes EK; Falch JA; Kaastad TS; Kristiansen IS; Nordsletten L; Stensvold I; Meyer HE
    Bone; 2001 Nov; 29(5):413-8. PubMed ID: 11704490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence rates of fragility hip fracture in middle-aged and elderly men and women in southern Norway.
    Diamantopoulos AP; Rohde G; Johnsrud I; Skoie IM; Johnsen V; Hochberg M; Haugeberg G
    Age Ageing; 2012 Jan; 41(1):86-92. PubMed ID: 21896555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued decline in hip fracture incidence in Norway: a NOREPOS study.
    Søgaard AJ; Holvik K; Meyer HE; Tell GS; Gjesdal CG; Emaus N; Grimnes G; Schei B; Forsmo S; Omsland TK
    Osteoporos Int; 2016 Jul; 27(7):2217-2222. PubMed ID: 26902091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Height and body mass index in Oslo, Norway, compared to other regions of Europe: do they explain differences in the incidence of hip fracture? European Vertebral Osteoporosis Study Group.
    Meyer HE; Falch JA; O'Neill T; Tverdal A; Varlow J
    Bone; 1995 Oct; 17(4):347-50. PubMed ID: 8573406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of hormone replacement therapy on bone mineral density and axial transmission ultrasound measurements in cortical bone.
    Knapp KM; Blake GM; Spector TD; Fogelman I
    Osteoporos Int; 2003 Jun; 14(4):289-94. PubMed ID: 12730793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
    Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
    Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hip fracture incidence in the high-risk area Oslo continues to decline.
    Hestnes I; Solberg LB; Meyer HE; Sundet M; Rimal R; Nordsletten L; Hakestad KA
    Osteoporos Int; 2024 Jun; ():. PubMed ID: 38922398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.